- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
Central Data Repository
Explore the Central Data Repository: Use the filters and keyword search box on the left to find relevant studies. As you refine your search, the map and study list will automatically update to reflect your selections. Selecting a study from the list will provide detailed information about the specific study in question. A full legend can be found here
{content}
Study list
- Adults (18-64 years)
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Adults (18-64 years)
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Pharmacological intervention
- Allopurinol
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Neurostimulation
- Adults (18-64 years)
- Fragile population
- People at high risk of STIs
- Immunocompromised host
- PrEP users
- People living with HIV
- Hospital
- Outpatient clinic
- Infectious diseases unit
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- Healthcare workers
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Immunoadsorption
- Adults (18-64 years)
- General population
- Monkeypox virus
- Mpox
- Pharmacological intervention
- Vaccination
- mRNA-1769
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- People at high risk of STIs
- PrEP users
- People living with HIV
- Hospital
- Outpatient clinic
- Monkeypox virus
- Mpox
- Blood sample
- Pharmacological intervention
- Vaccination
- MVA-BN
- Adults (18-64 years)
- General population
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Pharmacological intervention
- vasodilator
- Vericiguat
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Pharmacological intervention
- BC 007
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Pharmacological intervention
- Probiotic
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Pharmacological intervention
- Pycnogenol
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Hydrotherapy
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- Physical activity
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Immunoadsorption
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- Fimo Health App
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Fragile population
- Hospital
- Emergency department
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab